Heidelberg Pharma AG (HPHA.DE)
EUR 2.38
(-0.42%)
EUR 2.38
(-0.42%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -20.34 Million EUR | -3.27% |
| 2022 | -19.7 Million EUR | 26.02% |
| 2021 | -26.63 Million EUR | -44.95% |
| 2020 | -18.37 Million EUR | -81.05% |
| 2019 | -10.14 Million EUR | 13.06% |
| 2018 | -11.67 Million EUR | -6.4% |
| 2017 | -10.97 Million EUR | -71.7% |
| 2016 | -6.38 Million EUR | 2.48% |
| 2015 | -6.55 Million EUR | -14.92% |
| 2014 | -5.7 Million EUR | -13.1% |
| 2013 | -5.04 Million EUR | 46.33% |
| 2012 | -9.39 Million EUR | 32.57% |
| 2011 | -13.92 Million EUR | 39.69% |
| 2010 | -23.08 Million EUR | -81.39% |
| 2009 | -12.72 Million EUR | 37.75% |
| 2008 | -20.44 Million EUR | 0.0% |
| 2007 | - EUR | 0.0% |
| 2006 | - EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -4.49 Million EUR | 0.31% |
| 2024 Q2 | -4.17 Million EUR | 7.19% |
| 2024 Q3 | -5.59 Million EUR | -34.09% |
| 2023 Q2 | -9.38 Million EUR | -43.04% |
| 2023 Q1 | -6.56 Million EUR | -1.32% |
| 2023 Q3 | 113.11 Thousand EUR | 101.2% |
| 2023 Q4 | -4.5 Million EUR | -4085.34% |
| 2023 FY | -20.34 Million EUR | -3.27% |
| 2022 Q4 | -6.47 Million EUR | -40.21% |
| 2022 Q1 | -7.4 Million EUR | -1.66% |
| 2022 Q2 | -1.35 Million EUR | 81.67% |
| 2022 Q3 | -4.61 Million EUR | -240.16% |
| 2022 FY | -19.7 Million EUR | 26.02% |
| 2021 Q1 | -6.32 Million EUR | -7.11% |
| 2021 Q3 | -5.76 Million EUR | 14.86% |
| 2021 Q4 | -7.28 Million EUR | -26.46% |
| 2021 Q2 | -6.76 Million EUR | -7.09% |
| 2021 FY | -26.63 Million EUR | -44.95% |
| 2020 Q1 | -4.57 Million EUR | -1.58% |
| 2020 FY | -18.37 Million EUR | -81.05% |
| 2020 Q2 | -4.85 Million EUR | -6.16% |
| 2020 Q3 | -3.04 Million EUR | 37.24% |
| 2020 Q4 | -5.9 Million EUR | -93.78% |
| 2019 FY | -10.14 Million EUR | 13.06% |
| 2019 Q1 | -3.08 Million EUR | 27.52% |
| 2019 Q2 | -1.24 Million EUR | 59.62% |
| 2019 Q3 | -1.31 Million EUR | -5.98% |
| 2019 Q4 | -4.49 Million EUR | -240.97% |
| 2018 Q1 | -2.41 Million EUR | 27.96% |
| 2018 Q2 | -2.29 Million EUR | 4.78% |
| 2018 FY | -11.67 Million EUR | -6.4% |
| 2018 Q4 | -4.25 Million EUR | -57.32% |
| 2018 Q3 | -2.7 Million EUR | -17.66% |
| 2017 FY | -10.97 Million EUR | -71.7% |
| 2017 Q3 | -3.36 Million EUR | -46.49% |
| 2017 Q4 | -3.35 Million EUR | 0.28% |
| 2017 Q2 | -2.29 Million EUR | -16.75% |
| 2017 Q1 | -1.96 Million EUR | 13.33% |
| 2016 Q2 | -1.3 Million EUR | -20.9% |
| 2016 Q3 | -1.73 Million EUR | -32.94% |
| 2016 FY | -6.38 Million EUR | 2.48% |
| 2016 Q1 | -1.08 Million EUR | 64.03% |
| 2016 Q4 | -2.26 Million EUR | -30.57% |
| 2015 Q2 | -822 Thousand EUR | 23.5% |
| 2015 FY | -6.55 Million EUR | -14.92% |
| 2015 Q1 | -1.07 Million EUR | 72.38% |
| 2015 Q4 | -3 Million EUR | -81.8% |
| 2015 Q3 | -1.65 Million EUR | -100.97% |
| 2014 FY | -5.7 Million EUR | -13.1% |
| 2014 Q4 | -3.89 Million EUR | -250.79% |
| 2014 Q3 | 2.58 Million EUR | 271.2% |
| 2014 Q2 | -1.5 Million EUR | 47.74% |
| 2014 Q1 | -2.88 Million EUR | -165.97% |
| 2013 Q4 | -1.08 Million EUR | -160.64% |
| 2013 FY | -5.04 Million EUR | 46.33% |
| 2013 Q1 | -1.97 Million EUR | -0.35% |
| 2013 Q2 | -1.56 Million EUR | 21.04% |
| 2013 Q3 | -416 Thousand EUR | 73.37% |
| 2012 FY | -9.39 Million EUR | 32.57% |
| 2012 Q1 | -2.55 Million EUR | -267.08% |
| 2012 Q2 | -3.05 Million EUR | -19.52% |
| 2012 Q3 | -1.81 Million EUR | 40.73% |
| 2012 Q4 | -1.97 Million EUR | -8.9% |
| 2011 Q1 | -5.95 Million EUR | -1.49% |
| 2011 Q3 | -2.6 Million EUR | 44.11% |
| 2011 Q2 | -4.66 Million EUR | 21.62% |
| 2011 FY | -13.92 Million EUR | 39.69% |
| 2011 Q4 | -696.06 Thousand EUR | 73.31% |
| 2010 FY | -23.08 Million EUR | -81.39% |
| 2010 Q2 | -6.15 Million EUR | -13.99% |
| 2010 Q3 | -5.66 Million EUR | 7.95% |
| 2010 Q1 | -5.4 Million EUR | -223.4% |
| 2010 Q4 | -5.86 Million EUR | -3.54% |
| 2009 Q4 | -1.66 Million EUR | -168.35% |
| 2009 Q3 | -622.25 Thousand EUR | 86.8% |
| 2009 Q2 | -4.71 Million EUR | 17.68% |
| 2009 Q1 | -5.72 Million EUR | 0.0% |
| 2009 FY | -12.72 Million EUR | 37.75% |
| 2008 FY | -20.44 Million EUR | 0.0% |
| 2007 FY | - EUR | 0.0% |
| 2006 FY | - EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| BioNTech SE | 930.3 Million EUR | 102.187% |
| CureVac N.V. | -260.16 Million EUR | 92.179% |
| Biotest Aktiengesellschaft | 127 Million EUR | 116.021% |
| Biotest Aktiengesellschaft | 127 Million EUR | 116.021% |
| BRAIN Biotech AG | -8.27 Million EUR | -145.76% |
| Formycon AG | 75.79 Million EUR | 126.844% |
| Medigene AG | -16.17 Million EUR | -25.774% |